Welcome to our dedicated page for SCOTTS MIRACLE-GRO CO SEC filings (Ticker: SMG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SCOTTS MIRACLE-GRO CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SCOTTS MIRACLE-GRO CO's regulatory disclosures and financial reporting.
Scotts Miracle-Gro Chairman and CEO James Hagedorn reported an acquisition of phantom stock under an incentive arrangement. He was granted 1,194.235 phantom stock units at a reference price of $69.78 per unit, increasing his directly held phantom stock balance to 234,996.506 units.
Each phantom stock unit represents the right to receive one common share of Scotts Miracle-Gro or its cash value. According to the terms, the phantom stock is payable in cash after his employment with the company ends, and he may transfer these units into an alternative investment at any time.
SCOTTS MIRACLE-GRO CO executive Mark J. Scheiwer, EVP, CFO & CAO, purchased 693 common shares in an open-market transaction at a price of $71.435 per share. After this purchase, he directly owned 15,369.741 common shares, with an additional 493.482 shares held indirectly through a 401(k) plan.
The Scotts Miracle-Gro Company filed an 8-K to reflect a major reporting change after deciding in the first quarter of fiscal 2026 that its Hawthorne business meets the criteria to be classified as held for sale. Hawthorne is now treated as a discontinued operation, and all prior periods have been recast accordingly.
The company furnished unaudited, revised GAAP and non-GAAP results for fiscal 2024 and 2025, including segment data and Adjusted EBITDA. For the twelve months ended September 30, 2025, revised net sales from continuing operations were $3,255.8 million, net income from continuing operations was $182.1 million, and Adjusted EBITDA was $569.7 million. The revised presentation increases the focus on the U.S. Consumer and Other businesses by removing Hawthorne’s results from continuing operations.
Hagedorn Partnership, L.P., a director and 10% owner of Scotts Miracle-Gro, reported an open-market sale of common shares. On 02/12/2026, the partnership sold 50,000 common shares at a weighted average price of $66.3987 per share, with trades ranging from $65.98 to $66.64. After this transaction, it beneficially owned 13,167,641 common shares directly.
A shareholder of a NYSE-listed company has filed a notice of proposed sale under Rule 144 for 50,000 shares of common stock. The filing lists an aggregate market value of $3,319,937.60 for these shares, based on the disclosure in the form.
The shares are to be sold through Merrill, 8890 Lyra Drive, 5th Floor, Columbus, OH 43240, with an approximate sale date of February 12, 2026 on the NYSE. The form notes that there were 58,039,753 shares outstanding of this class at the time of the notice.
The seller originally acquired the 50,000 common shares on June 16, 1995 via a partnership contribution from Community Fund & General Partnership, with payment made on the same date. The signer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Scotts Miracle-Gro director Adam Hanft reported a routine equity award conversion. On February 3, 2026, he exercised dividend equivalent rights tied to restricted stock units, converting 336 Dividend Equivalent Rights into 336 Common Shares at a price of $0 per share. Following the transaction, he beneficially owned 45,018 Common Shares directly and 447 Dividend Equivalent Rights. The footnotes explain that restricted stock units convert into common shares on a one-for-one basis and reference a prior grant of 2,553 restricted stock units awarded on February 3, 2023 with vesting on February 3, 2024.
Scotts Miracle-Gro director Mark D. Kingdon reported an equity award transaction. On February 3, 2026, restricted stock units converted into 165 common shares at a price of $0, reflecting a vesting-related acquisition rather than an open-market purchase.
Following this transaction, Kingdon directly owns 11,658 common shares and 447 dividend equivalent rights. The filing notes that restricted stock units convert into common shares on a one-for-one basis and that he had been granted 1,497 restricted stock units with accruing dividend equivalent rights on July 13, 2023, vesting on February 3, 2024.
Scotts Miracle-Gro Chairman and CEO James Hagedorn reported a disposition of 16,677 Common Shares of SCOTTS MIRACLE-GRO on February 3, 2026 at $63.69 per share under transaction code F. After this transaction, he directly holds 87,435.9728 Common Shares.
He also reports indirect holdings of 31,533.64 Common Shares through a 401(k) plan and 997,910 Common Shares indirectly through Hagedorn Partnership, L.P. The filing states he may be deemed a more than 10% beneficial owner based on his proportionate interest in this partnership.
Scotts Miracle-Gro executive Christopher Hagedorn reported a small share disposition. On 02/03/2026, a Form 4 filing shows 2,588 common shares of Scotts Miracle-Gro were disposed of at a price of $63.69 per share. Following this transaction, Hagedorn directly owned 57,527.4664 common shares of the company.
Scotts Miracle-Gro director David C. Evans reported a stock-based award conversion. On February 3, 2026, 336 common shares of Scotts Miracle-Gro were acquired at a price of $0 per share following the exercise of dividend equivalent rights tied to prior restricted stock unit awards.
After this transaction, Evans directly owned 28,060 common shares and 447 dividend equivalent rights. The filing reflects routine equity compensation activity, where previously granted restricted stock units and associated dividend equivalents convert into common shares on a one-for-one basis.